Medicare utilization — DR. ELENA F FLAGG (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 94,800 | 31 | $0 | $369,951 |
| J3262 | Injection, tocilizumab, 1 mg | 85,920 | 21 | $0 | $394,007 |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 34,425 | 50 | $0 | $1,149,777 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 23,381 | 66 | $0 | $613,903 |
| J0897 | Injection, denosumab, 1 mg | 15,780 | 166 | $0 | $291,362 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·